他克莫司联合311 nm窄谱中波紫外线治疗掌跖脓疱病疗效与安全性分析

Abstract
Figure/Table
References
Related Citation (10)

Download: PDF (0 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To the efficacy and safety of using the method of tacrolimus combined with 311 nm narrow-spectrum uvb rays to treat palmoplantar pustulosis (PPP).Methods A total of 99 patients with moderate or severe PPP were enrolled in the study and were randomized into either the treatment group or control group.The treatment group used the method of 0.1% tacrolimus ointment combined with 311 nm narrow-spectrum uvb rays to treat PPP,the control group only for narrow spectrum uvb rays irradiation.After treatment for 2 weeks,4 weeks,6 weeks,8 weeks to determine efficacy,record adverse reactions.Results After treatment of 8 weeks the total scores of skin findings at the last observation were (2.61±1.48) in the treatment group and (3.75±1.99) in the control group,the difference was statistically significant. In particularly,the score of pustules/vesicles drastically decreased in the treatment group.In terms of safety,the incidence of adverse reactions in the treatment group and control group were 13.7% and 8.3%.There was no difference in the incidence of adverse reactions.Conclusion The treatment of tacrolimus combined 311 nm narrow-spectrum uvb rays is effective and highly safe in the management of PPP.

Key words： palmoplantar pustulosis tacrolimus narrow-spectrum uvb rays effect security

Received: 05 January 2017

PACS:

R753

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	WANG Xuehong
	XUE Xinxin
	DONG Yanxia
	XU Wen
	MA Qiang

Cite this article:

WANG Xuehong,XUE Xinxin,DONG Yanxia, et al. The analysis of effect and safety of tacrolimus combined with 311 nm narrow-spectrum uvbrays to treat palmoplantar pustulosis[J]. 滨州医学院学报, 2017, 40(2): 97-99.

URL:

http://manu58.magtech.com.cn/Jwk_bzyxy/EN/ OR http://manu58.magtech.com.cn/Jwk_bzyxy/EN/Y2017/V40/I2/97

[1] Hagforsen E,Hedstrand H,Nyberg F,et al.Novel findings of Langerhans cells and interleukin-17 expression in relation to the acrosyringium and pustule in palmoplantar pustulosis[J].Br J Dermatol,2010,163(3):572-579.
[2] Murakami M,Ohtake T,Horibe Y,et al.Acrosyringium is the main site of the vesicle/pustule formation in palmoplantar pustulosis[J].Invest Dermatol,2010,130(8):2010-2016.
[3] Murakami M,Hagforsen E,Morhenn V,et al.Patients with palmoplantar pustulosis have increased IL-17 and IL-22 levels both in the lesion and serum[J].Exp Dermatol,2011,20(10):845-847.
[4] Murakami M,Kaneko T,Nakatsuji T,et al.Vesicular LL-37 contributes to inflammation of the lesional skin of palmoplantar pustulosis[J].PLoS ONE,2014,9(10):e110677.
[5] Novak N,Kwiek B,Bieber T.The mode of topical immunom odulators in the immunological network of atopic dermatitis[J].Clin Exp Dermatol,2005,30(1):160-164.
[6] 钟彩梅,孙乐栋,曾抗,等.0.1%他克莫司软膏治疗寻常性银屑病的临床观察[J].临床皮肤科杂志,2010,39(8):531-532.
[7] 赵娜, 晋红中.外用他克莫司与卡泊三醇治疗斑块状银屑病的疗效与安全性评价[J].临床皮肤科杂志,2012,41(10):626-628.
[8] Kawada A,Matsuda H,Oiso N.Efficacy and safety of targeted narrowband ultraviolet B therapy using a flat-type fluorescent lamp for the treatment of palmoplantar pustulosis[J].J Dermatol,2013,40(9):754-755.
[9] 赵辨. 中国临床皮肤病学[M].4版. 南京:江苏科学技术出版社,2009.
[10] 李玉湘,傅强,张秀春,等.复方氟米松乳膏联合窄谱中波紫外线治疗掌跖脓疱病63例临床疗效观察[J].临床皮肤科杂志,2013,42(4):257-258.
[11] Umezawa Y,Nakagawa H,Tamaki K.Phase III clinical study of maxacalcitol ointment in patients with palmoplantar pustulosis:A randomized,double-blind,placebo-controlled trial[J].J Dermatol,2016,43(3):288-293.
[12] Lynde C W,Poulin Y,Vender R,et al.Interleukin 17A:toward a new understanding of psoriasis pathogenesis[J].J Am Acad Dermatol,2014,71(1):141-150.
[13] Johnson-Huang L M,Suárez-Fari as M, Sullivan-Whalen M,et al.Effective narrow-band UVB radiation therapy suppresses the IL-23/IL-17 axis in normalized psoriasis plaques[J].J Invest Dermatol.2010 Nov;130(11):2654-63.
[14] Almutawa F,Alnomair N,Wang Y,et al.Systematic review of UV based therapy for psoriasis[J].Am J Clin Dermatol,2013,14(2):87-109.
[15] Guttman-Yassky E,Nograles K E,Krueger J G.Contrasting pathogenesis of atopic dermatitis and psoriasis-part Ⅱ:immune cell subsets and therapeutic concepts[J].J Allergy Clin Immunol,2011,127(6):1420-1432.
[16] Wolk K,Haugen H S,Xu W,et al.IL-22 and IL-20 are key mediators of the epidermal alterations in psoriasis while IL-17 and IFN-gamma are not[J].J Mol Med (Berl),2009,87(5):523-536.
[17] Rueda-Gotor J,González-Gay M A,Blanco Alonso R,et al.Successful effect of tocilizumab in anti-TNF-α-induced palmoplantar pustulosis in rheumatoid arthritis[J].Joint Bone Spine,2012,79(5):510-513.